Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Health consequences
Sessions
Wednesday, 23 November
09:00
Ensuring adequate pain relief whilst reducing addiction risk: lessons learnt and the way forward
09:00
to
10:30
Main stage
Plenary session
10:50
Drug treatment
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Emerging changes in Europe's cannabis situation: policy preparedness and responses to a dynamic situation
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
Gaming and gambling: Characteristics, harms, correlates, and treatment
10:50
to
12:20
Networking zone 2 (N2)
e-poster guided tour
Improving knowledge, taking action
10:50
to
12:20
Networking zone 1 (N1)
e-poster guided tour
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
13:20
Cannabis
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
Drug problems, perspectives and patterns of use
13:20
to
14:50
Networking zone 4 (N4)
Short communication session
Gambling epidemiology and new trends
13:20
to
14:50
Insights zone 3 (I3)
Oral presentation session
Hepatitis C epidemiology and prevention
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Structured session
15:00
Alcohol use and AUD during COVID-19 pandemic
15:00
to
16:30
Central square 1 (C1)
Oral presentation session
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Structured session
Estimating harm
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Estimating prevalence
15:00
to
16:30
Knowledge market 4 (K4)
Oral presentation session
Injecting-related infections and drug surveillance
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
16:50
Alcohol use disorder treatment and its epidemiology
16:50
to
18:20
Central square 1 (C1)
Oral presentation session
Economic recessions, COVID-19, socio-determinants of drug use and its harms: deaths of despair?
16:50
to
18:20
Central square 4 (C4)
Workshop
Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements
16:50
to
18:20
Knowledge market 3 (K3)
Structured session
Improving the health of people who use drugs
16:50
to
18:20
Networking zone 4 (N4)
Short communication session
Treatment options for drug users in prisons in Central Asia and Germany
16:50
to
18:20
Networking zone 1 (N1)
Structured session
Thursday, 24 November
09:00
Re-imagine recovery
09:00
to
10:30
Main stage
Plenary session
10:50
Alcohol policies
10:50
to
12:20
Central square 1 (C1)
Oral presentation session
Cannabis use and purchase behaviours in Canada, United States, Australia, and New Zealand: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
Current international evidence on prevalence and perceptions of Heated Tobacco Products (HTPs)
10:50
to
12:20
Insights zone 4 (I4)
Structured session
How can we improve global coverage of interventions to reduce drug-related harms?
10:50
to
12:20
Main stage
Structured session
13:20
Cannabis and tobacco co-use: A ‘joint’ challenge for research and practice
13:20
to
14:50
Knowledge market 1 (K1)
Structured session
Hepatitis C testing and treatment
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
Methods and Problems with Estimating Prevalence of People Who Inject Drugs, studies and debate on how to get better and more consistent estimates in Europe and Rest of the World
13:20
to
14:50
Central square 2 (C2)
Structured session
Understanding problematic gambling
13:20
to
14:50
Insights zone 3 (I3)
Oral presentation session
15:00
Alcohol epidemiology and interventions
15:00
to
16:30
Networking zone 3 (N3)
Short communication session
Client-centered approaches
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Insights into acute recreational drug and new psychoactive substance toxicity – an update from the Euro-DEN Plus Project
15:00
to
16:30
Central square 2 (C2)
Structured session
Models to improve the health of people who inject drugs
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
Prevention, testing and treatment of Hepatitis C and other infections
15:00
to
16:30
Networking zone 4 (N4)
Short communication session
The global gambling industry: Structures, tactics, and networks of impact
15:00
to
16:30
Insights zone 3 (I3)
Structured session
16:50
Substance use, suicide and self-harm: epidemiology and prevention
16:50
to
18:20
Main stage
Structured session
Unpacking the neurobiology of cannabis use disorders and cannabinoids: findings from neuroimaging and experimental studies across different ages and world regions
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
18:30
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Structured session
Friday, 25 November
09:00
Alcohol addiction; new knowledge on politics, risks, treatments and outcomes
Social inequality in drinking, underage drinking and alcohol industry
09:00
to
10:30
Main stage
Plenary session
Insights from treatment II
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
10:50
EUFAS/EAR European Addiction Award
Alcohol - no ordinary commodity, alcohol policies and The Gut-Brain Axis in AUD
10:50
to
12:20
Main stage
Structured session
COVID-19-adapted addiction services and impact for service users
10:50
to
12:20
Insights zone 4 (I4)
Structured session
Gender differences and gender identities in drug use, addiction and interventions: why gender matters
10:50
to
12:20
Networking zone 3 (N3)
Structured session
Mortality among people who use drugs
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Recreational drug use and risk
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Substance use and sexual behaviours
10:50
to
12:20
Knowledge market 4 (K4)
Oral presentation session
Technological addictions in the 21st century
10:50
to
12:20
Networking zone 2 (N2)
e-poster guided tour
13:20
Alcohol psychology and some epidemiology
13:20
to
14:50
Networking zone 4 (N4)
Short communication session
Challenging issues for drug research
13:20
to
14:50
Central square 1 (C1)
Oral presentation session
Overdose prevention
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
Stress and Addiction: Updates on the Chicken or Egg question
13:20
to
14:50
Central square 4 (C4)
Structured session
Substance use consequences and concerns
13:20
to
14:50
Networking zone 1 (N1)
e-poster guided tour
Substance use, mental health risk and suicide
13:20
to
14:50
Knowledge market 2 (K2)
Oral presentation session
15:30
Closing keynote: Providing care in a time of war — perspectives from Ukraine
15:30
to
16:00
Main stage
Plenary session
Presentations
Wednesday, 23 November
09:00
Keynote presentation
EFIC recommendations: When to use opioids for chronic pain and when not to
09:00
to
10:30
Main stage
Winfried Häuser
Keynote presentation
Pain and the opioid overdose crisis in the U.S.: experiences, lessons learned, and the path forward
09:00
to
10:30
Main stage
Christopher M. Jones
Keynote presentation
Changing perspectives on the use of medicines for pain
09:00
to
10:30
Main stage
Cathy Stannard
10:50
Oral presentation
A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation
I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use
10:50
to
12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation
Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada
10:50
to
12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation
Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC
10:50
to
12:20
Knowledge market 3 (K3)
Samara Mayer
e-poster
Gaming disorder associated to comorbid disorders in an immigrant adolescent: A clinical case study.
10:50
to
12:20
Networking zone 2 (N2)
Carla Andrade
e-poster
The perceived importance of a Therapeutical Contract in a CBT based treatment of problem gamblers
10:50
to
12:20
Networking zone 2 (N2)
Pedro Hubert
e-poster
Gambling in Ireland: profile of cases from an analysis of a national treatment reporting system.
10:50
to
12:20
Networking zone 2 (N2)
Ita Condron
e-poster
At odds with success; identifying and responding to gambling behaviour among irish undergraduate students
10:50
to
12:20
Networking zone 2 (N2)
Emmett Tuite
e-poster
Bet You Can Help: Addressing gambling related harms through a universal public health education approach
10:50
to
12:20
Networking zone 2 (N2)
Neil Platt
e-poster
Industry self-regulation vs legal regulation: lower compliance with loot box probability disclosure requirements in the UK than in China
10:50
to
12:20
Networking zone 2 (N2)
Leon Y. Xiao
e-poster
The relationship between gaming, self-harm, resilience, loneliness, and attachment in adulthood
10:50
to
12:20
Networking zone 2 (N2)
Jaroslava Suchá
e-poster
The Questionnaire of Digital Game Playing (QDGP)
10:50
to
12:20
Networking zone 2 (N2)
Martin Dolejš
e-poster
Gambling Motives and Offshore Gambling: A Finnish Population Study
10:50
to
12:20
Networking zone 2 (N2)
Heli Hagfors
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
e-poster
Drug death related bereavement and recovery (The END-project)
10:50
to
12:20
Networking zone 1 (N1)
Birthe Møgster
e-poster
Effects of prolonged diacetylmorphine take-home prescription in Heroin assisted treatment in Switzerland
10:50
to
12:20
Networking zone 1 (N1)
Jonas Montagna
e-poster
Predicting the long-term effect of e-cigarette use on population health: A systematic review of modelling studies
10:50
to
12:20
Networking zone 1 (N1)
Giang Vu
e-poster
Barriers and Facilitators to Accessing Inpatient and Community Substance Use Treatment and Harm Reduction Services for People Who Use Drugs in Muslim Communities: A Systematic Narrative Review of Studies on Service Users and Providers Experiences
10:50
to
12:20
Networking zone 1 (N1)
Qutba Al Ghafri
e-poster
Prolonged DAM-take-home in times of Covid-19:harm reduction or increase?
10:50
to
12:20
Networking zone 1 (N1)
Franciska Brezan
e-poster
Prevalence of HCV infection in vulnerable populations: DETECT-C program a real contribution to hepatitis C elimination in these groups in Spain
10:50
to
12:20
Networking zone 1 (N1)
Francisco Pascual
e-poster
ABC Training for Alcohol Use During an Abstinence Challenge (IkPas/NoThanks!): a pilot study
10:50
to
12:20
Networking zone 1 (N1)
Ting Pan
Oral presentation
2. Medical use of cannabis and cannabinoids: an overview of evidence
10:50
to
12:20
Knowledge market 4 (K4)
Mafalda Pardal
Oral presentation
5. Treatment of cannabis-related problems in Europe: a typology and evidence overview
10:50
to
12:20
Knowledge market 4 (K4)
Daniel Feingold
Oral presentation
3. Cannabis-related effects and harms: a scientific overview
10:50
to
12:20
Knowledge market 4 (K4)
Jakob Manthey
Oral presentation
4. Harm reduction for cannabis related problems in Europe and beyond
10:50
to
12:20
Knowledge market 4 (K4)
Iciar Indave
Introduction
1. Setting the scene: recent cannabis policy developments in European countries
10:50
to
12:20
Knowledge market 4 (K4)
Liesbeth Vandam
13:20
Oral presentation
The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in UK
13:20
to
14:50
Knowledge market 3 (K3)
Peter Vickerman
Oral presentation
Global incidence of hepatitis C virus (HCV) and HIV infection among people who inject drugs: A systematic review and meta-analysis
13:20
to
14:50
Knowledge market 3 (K3)
Adelina Artenie
Oral presentation
Assessing the impact of COVID-19 and associated control measures on interventions to prevent drug-related harm among people who inject drugs in Scotland
13:20
to
14:50
Knowledge market 3 (K3)
Kirsten Trayner
Oral presentation
The Contribution of Unstable Housing to HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs Globally, Regionally, and at Country Level: A Modelling Study
13:20
to
14:50
Knowledge market 3 (K3)
Jack Stone
Oral presentation
Cryptocurrency trading as behavioral addiction: cross-sectional and longitudinal perspective from Finland
13:20
to
14:50
Insights zone 3 (I3)
Atte Oksanen
Oral presentation
Online gambling and associated harms during the COVID-19 pandemic: A population study
13:20
to
14:50
Insights zone 3 (I3)
Sylvia Kairouz
Oral presentation
Online gambling and F2P games in Canada: portrait and trends
13:20
to
14:50
Insights zone 3 (I3)
Annie-claude Savard
Oral presentation
Problem gambling among European adolescents: potential risk of gambling products and online gambling
13:20
to
14:50
Insights zone 3 (I3)
Elisa Benedetti
e-poster
Crosstalk between autophagic intermediaries in the event of neurotoxic effects mediated by Synthetic Cannabinoids in NG108-15 cells
13:20
to
14:50
Networking zone 2 (N2)
Catarina Teixeira
Short communication
Anabolic-androgenic steroid dependence and muscle dysmorphia: an exploratory network analysis
13:20
to
14:50
Networking zone 4 (N4)
Morgan Scarth
e-poster
Treating cannabis use disorder in young adults with text-delivered peer network counseling: A large, multi-site, randomized clinical trial.
13:20
to
14:50
Networking zone 2 (N2)
Michael Mason
Short communication
The use of psychoactive substances among residents of long-term care facilities for the elderly : perspectives of residents, providers and administrators on the current situation, challenges and improvement of practices.
13:20
to
14:50
Networking zone 4 (N4)
Emile Bernier
e-poster
The arrival of Edibles in Quebec cannabis market : what can be done to minimize the health impact?
13:20
to
14:50
Networking zone 2 (N2)
Julie Loslier
Short communication
Sharing is caring: Expressions and dynamics within the social supply of illegal drugs
13:20
to
14:50
Networking zone 4 (N4)
Olga S. Cruz
e-poster
What difference will 2.5 grams make? Canada responds to British Columbia’s overdose crisis by agreeing to decriminalize possession of small amounts of drugs
13:20
to
14:50
Networking zone 2 (N2)
Lori Hanson
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
e-poster
Prevalence and correlates of cannabis use for medicinal reasons – an Australian cross- sectional study
13:20
to
14:50
Networking zone 2 (N2)
Janni Leung
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
e-poster
Fifth of the inhabitants of Slovenia has already used cannabis or cannabis-derived products for health purposes or is considering it
13:20
to
14:50
Networking zone 2 (N2)
Ada Hocevar Grom
Discussion
Perspectives from government and civil society member(s) of the ECDC and EMCDDA expert panel on the key areas of intervention
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Anne Bergenstrom,
Anna Tarján,
Mat Southwell,
Viktor Mravcik,
Annette Verster,
Slava Kushakov
e-poster
The synthetic cannabinoid ADB-FUBINACA modulates epigenetic mechanisms during in vitro neuronal differentiation at biologically relevant concentrations
13:20
to
14:50
Networking zone 2 (N2)
Felix Carvalho
Short communication
Substance use and re-imprisonment: A longitudinal study of the Norwegian Offender Mental Health and Addiction (NorMA) cohort
13:20
to
14:50
Networking zone 4 (N4)
Nicoline Lokdam
e-poster
Profiles of individuals with cannabis-related disorders
13:20
to
14:50
Networking zone 2 (N2)
Marie-Josée Fleury
Short communication
The age of onset and quitting of drug use is rising
13:20
to
14:50
Networking zone 4 (N4)
Andreja Drev
e-poster
The effects of Synthetic Cannabinoids ADB-FUBINACA, AMB-FUBINACA, AB-CHMINACA and HU-308 on Differentiation and Proliferation of Brain NG108-15 Cells
13:20
to
14:50
Networking zone 2 (N2)
Carolina Freitas
Short communication
The impact of music on the addictive trajectory: perspective from young adults who experience homelessness.
13:20
to
14:50
Networking zone 4 (N4)
Elise Cournoyer Lemaire
15:00
Oral presentation
Temporal changes in alcohol consumption associated with the COVID-19 interventions in Belgium: a wastewater-based approach
15:00
to
16:30
Central square 1 (C1)
Maarten Quireyns
Oral presentation
Impacts of changes in alcohol consumption patterns during the first 2020 COVID-19 restrictions for people with and without mental health and neurodevelopmental conditions: A cross sectional study in 13 countries
15:00
to
16:30
Central square 1 (C1)
Gail Gilchrist
Oral presentation
Severe COVID-19 cases among patients admitted to treatment for alcohol and drug use disorders in Catalonia
15:00
to
16:30
Central square 1 (C1)
Jorge Palacio-Vieira
Oral presentation
Disentangling the 'COVID-19 alcohol paradox': reasons for changes in alcohol-specific disease burden during the COVID-19 pandemic in Germany
15:00
to
16:30
Central square 1 (C1)
Jakob Manthey
Oral presentation
Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.
15:00
to
16:30
Knowledge market 3 (K3)
Magdalena Harris
Oral presentation
Analysis of drugs in used syringes from sentinel European cities, 2020
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Seyler
Oral presentation
The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study
15:00
to
16:30
Knowledge market 3 (K3)
Samantha Colledge-Frisby
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
15:00
to
16:30
Knowledge market 4 (K4)
Vivian Hope
Oral presentation
Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study
15:00
to
16:30
Knowledge market 4 (K4)
Gary Chan
Oral presentation
Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers
15:00
to
16:30
Knowledge market 4 (K4)
Kyla Thomas
Oral presentation
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study
15:00
to
16:30
Knowledge market 4 (K4)
Jason Grebely
Oral presentation
How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)
15:00
to
16:30
Knowledge market 4 (K4)
Nadine Hendrie
Oral presentation
Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Brothers
16:50
Oral presentation
1. The Impact of Economic Recessions on the Use of Illicit Drugs: a Systematic Review of Literature and a Meta-Analysis
16:50
to
18:20
Central square 4 (C4)
Claudia Costa Storti
Oral presentation
2. The impact of economic recessions on the harms of drug use and health responses, in Europe: a panel data analysis
16:50
to
18:20
Central square 4 (C4)
Bruno Casal
Oral presentation
3. Structural vulnerabilities and deaths of despair in Scotland, 1980-2021
16:50
to
18:20
Central square 4 (C4)
Mirjam Allik
Oral presentation
4. Economic conditions and opioids: An overview
16:50
to
18:20
Central square 4 (C4)
Sotiris Vandoros
Discussion
What lessons have we learn from past that apply to the COVID-19 induced recession? A structured debate
16:50
to
18:20
Central square 4 (C4)
Liesbeth Vandam
Oral presentation
Can alcohol abstinence orders reduce mortality? Insights from an individual-level analysis of 24/7 Sobriety
16:50
to
18:20
Central square 1 (C1)
Beau Kilmer
Oral presentation
Community involvement facilitating the discussion of alcohol use in primary care: A nominal group study
16:50
to
18:20
Central square 1 (C1)
Bram Pussig
Oral presentation
Modeling the Impact of a long-term horizon and multiple treatment episodes on the effectiveness and cost-effectiveness of alcohol treatment in the United States
16:50
to
18:20
Central square 1 (C1)
Carolina Barbosa
Oral presentation
Per capita alcohol consumption and alcohol-related harm: an analysis of long-term evidence from Nordic and Mediterranean countries
16:50
to
18:20
Central square 1 (C1)
Gregor Zwirn
Oral presentation
The modelled cost-effectiveness of two psychological treatments for the reduction of alcohol consumption in alcohol-dependent individuals
16:50
to
18:20
Central square 1 (C1)
Sergio Flores
Short communication
Peer involvement and intersectoral cooperation experiences in outreach work with people who use psychoactive substances: a scoping review
16:50
to
18:20
Networking zone 4 (N4)
João Pedro Ramos
Short communication
Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.
16:50
to
18:20
Networking zone 4 (N4)
Peter McCarron
Short communication
The role of a medically supervised injecting room in improving access to health and social services.
16:50
to
18:20
Networking zone 4 (N4)
Nico Clark
Short communication
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial
16:50
to
18:20
Networking zone 4 (N4)
Arne Skulberg
Oral presentation
Peer and Nursing-led Outreach Combined with Point-of-care HCV Testing to Decentralise HCV Care and Enhance HCV Treatment Among People Who Use Drugs: The REACH_U Project
16:50
to
18:20
Networking zone 4 (N4)
Cristiana Merendeiro
Short communication
Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network
16:50
to
18:20
Networking zone 4 (N4)
Tanja Schwarz
Short communication
Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study
16:50
to
18:20
Networking zone 4 (N4)
Catriona Matheson
Short communication
Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study
16:50
to
18:20
Networking zone 4 (N4)
Koharu Loulou Chayama
Oral presentation
1. The role of social work in agency processes - empirical study using the example of people who use illicit substances with a history of imprisonment
16:50
to
18:20
Networking zone 1 (N1)
Daniela Jamin
Oral presentation
2. Social work with drug users in a probation system of Kyrgyzstan
16:50
to
18:20
Networking zone 1 (N1)
Estebes uulu Tynchtyk
Oral presentation
3. Health and social welfare in prisons in the Republic of Kazakhstan – women with HIV and the role of the social worker
16:50
to
18:20
Networking zone 1 (N1)
Dalida Mukasheva
Short communication
Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway
16:50
to
18:20
Networking zone 4 (N4)
Siv-Elin Carlsen
Oral presentation
1. Interventions to enhance prevention of hepatitis C and HIV infection
16:50
to
18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation
2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle
16:50
to
18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation
3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation
4. Community-led initiatives to enhance prevention and treatment for hepatitis C
16:50
to
18:20
Knowledge market 3 (K3)
Judy Chang
Thursday, 24 November
09:00
Keynote presentation
Addiction Recovery: From Culture to Science
09:00
to
10:30
Main stage
John F. Kelly
Keynote presentation
One should not have to recover alone
09:00
to
10:30
Main stage
Charlotte Colman
Keynote presentation
Introduction to Treatment and Recovery Systems: England as a case example
09:00
to
10:30
Main stage
Ed Day
10:50
Oral presentation
4. Harm perceptions of heated tobacco products and vaping among students at Lithuanian universities
10:50
to
12:20
Insights zone 4 (I4)
Erikas Simonavičius
Oral presentation
5. It’s not what you’d term normal smoking’: A qualitative exploration of HTP user identity
10:50
to
12:20
Insights zone 4 (I4)
Katherine A. East
Oral presentation
1. Global Prevalence of Heated Tobacco Product Use: A Systematic Review and Meta-analysis
10:50
to
12:20
Insights zone 4 (I4)
Tianze Sun
Oral presentation
2. HTP prevalence in England and use for smoking cessation
10:50
to
12:20
Insights zone 4 (I4)
Harry Tattan-Birch
Oral presentation
3. Perceived health risks of heated tobacco products, tobacco cigarettes, and e-cigarettes: Findings from a populationbased cross-sectional household survey in Germany (DEBRA study)
10:50
to
12:20
Insights zone 4 (I4)
Stephanie Klosterhalfen
Oral presentation
Implementing a Moderate Alcohol Use Program for Indigenous People: A Stakeholder Perspective
10:50
to
12:20
Central square 1 (C1)
Pascale Alarie-vézina
Oral presentation
Simulation of Alcohol Control Policies for Health Equity (SIMAH): Study design and first results
10:50
to
12:20
Central square 1 (C1)
Charlotte Probst,
Robin Purshouse
Oral presentation
Noticed and then forgotten: gender in alcohol policy stakeholder responses to alcohol and violence
10:50
to
12:20
Central square 1 (C1)
David Moore
Oral presentation
Impact of introducing a minimum alcohol tax share in retail prices on alcohol-attributable mortality in the WHO European Region: a modelling study
10:50
to
12:20
Central square 1 (C1)
Pol Rovira Escarrà
Oral presentation
1. The International Cannabis Policy Study – Framework for evaluating cannabis legalization
10:50
to
12:20
Knowledge market 1 (K1)
David Hammond
Oral presentation
2. Patterns of problematic cannabis use among Canadian and US respondents between 2018 and 2020: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
Cesar Leos-Toro
Oral presentation
3. Perceptions of illegal and legal cannabis in Canada in the three years after cannabis legalization: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
TBD TBD
Oral presentation
1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms
10:50
to
12:20
Main stage
Louisa Degenhardt
Oral presentation
2. Successful models for implementation of harm reduction programmes
10:50
to
12:20
Main stage
Monica Ciupagea
Oral presentation
3. How can we improve data and mobilise funding for harm reduction support globally?
10:50
to
12:20
Main stage
Keith Sabin
Oral presentation
4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms
10:50
to
12:20
Main stage
Judy Chang
13:20
Oral presentation
Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study
13:20
to
14:50
Knowledge market 3 (K3)
Anna Conway
Oral presentation
Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis
13:20
to
14:50
Knowledge market 3 (K3)
Suzanne Fraser
Oral presentation
Simplified HCV management algorithm for methadone clinics: a pilot study in Ukraine
13:20
to
14:50
Knowledge market 3 (K3)
Kostyantyn Dumchev
Oral presentation
A novel hepatitis C intervention in Denmark to test and treat people who inject drugs
13:20
to
14:50
Knowledge market 3 (K3)
Jonas Demant
Oral presentation
Gambling addiction, gambling related harm and gambling problems - a knowledge synthesis and research agenda
13:20
to
14:50
Insights zone 3 (I3)
Antonius Van Rooij
Oral presentation
Clarifying escapism in the context of problem gambling and problem videogaming
13:20
to
14:50
Insights zone 3 (I3)
Chanel Larche
Oral presentation
Gender differences in gambling behaviour among Tunisian high school adolescents: MedSPAD 2021
13:20
to
14:50
Insights zone 3 (I3)
Rym Mallekh
Oral presentation
Competing framings of gambling as a distinct vs similar problem – boundary making with substance use and eating disorders.
13:20
to
14:50
Insights zone 3 (I3)
Eva Samuelsson
Oral presentation
Putting together the puzzle of gambling addiction
13:20
to
14:50
Insights zone 3 (I3)
Martin Busch
Oral presentation
2. Estimating the prevalence of opioid dependence in New South Wales from multiple data sources: case study application of a Bayesian modelling approach
13:20
to
14:50
Central square 2 (C2)
Hayley E. Jones
Oral presentation
3. Estimates of people who injected drugs within the past 12 months in France
13:20
to
14:50
Central square 2 (C2)
Eric Janssen
Oral presentation
4. How many people injected illicit drugs in the European Union in 2019?
13:20
to
14:50
Central square 2 (C2)
Filippo Pericoli
Oral presentation
1. Estimates of people who injected drugs within the last 12 months in Belgium
13:20
to
14:50
Central square 2 (C2)
Luk Van Baelen
Oral presentation
5. Updated global estimates of prevalence of People Who Inject Drugs and coverage of harm reduction – what has changed between 2017 and 2021
13:20
to
14:50
Central square 2 (C2)
Samantha Colledge-Frisby
Oral presentation
1. Association of cannabis and tobacco use with incident anxiety, mood and psychotic disorders: a systematic review
13:20
to
14:50
Knowledge market 1 (K1)
Chloe Burke
Oral presentation
3. The Cannabis And Tobacco Cessation Advice (CATCA) project: A mixed method study exploring UK stop smoking practitioners’ knowledge, attitudes and practices around co-use
13:20
to
14:50
Knowledge market 1 (K1)
Maria Duaso
Oral presentation
4. Changes in tobacco use among people with cannabis use disorder treated in programs
13:20
to
14:50
Knowledge market 1 (K1)
Cristina Martínez
Oral presentation
2. Quitting experiences, attitudes and beliefs amongst UK young adult co-smokers: A qualitative interview study
13:20
to
14:50
Knowledge market 1 (K1)
Hannah Walsh
15:00
Short communication
Social networks amongst people with alcohol dependence who frequently attend hospital: an exploratory qualitative study
15:00
to
16:30
Networking zone 3 (N3)
Stephanie Fincham-Campbell
Short communication
Alcohol and other drug use and treatment for Aboriginal Australians involved in the criminal justice system
15:00
to
16:30
Networking zone 3 (N3)
Michael Doyle
Short communication
Effectiveness of regulatory policies on online/digital/internet – mediated alcohol marketing: a systematic review
15:00
to
16:30
Networking zone 3 (N3)
Sandra Rados Krnel
Short communication
Outcomes of a health economic evaluation of digital alcohol and tobacco interventions for cancer survivors alongside randomized controlled trials
15:00
to
16:30
Networking zone 3 (N3)
Matthijs Blankers
Short communication
Impact of digital alcohol marketing on alcohol-related attitudes and alcohol consumption
15:00
to
16:30
Networking zone 3 (N3)
Wim Van Dalen
Short communication
Benefits and Challenges of Integrating Yoga in Government-Funded Substance Addiction Treatment Programs in India: Results from a Mixed Methods Research Study with Exploratory Sequential Design.
15:00
to
16:30
Networking zone 3 (N3)
Sebastian Perumbilly,
Jake Zoubek,
Aubrey Grodin
Short communication
The global burden of alcohol use disorders: methodological considerations
15:00
to
16:30
Networking zone 3 (N3)
Laura Jones
Short communication
Structured Leisure Activities (SLA) and Adolescent Alcohol Use
15:00
to
16:30
Networking zone 3 (N3)
Matea Belošević
Oral presentation
The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study
15:00
to
16:30
Knowledge market 3 (K3)
Kari Lancaster
Oral presentation
Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK
15:00
to
16:30
Knowledge market 3 (K3)
Julian Surey
Short communication
Transactional sex as a pathway for rising sexually transmitted infections amidst the opioid epidemic in the United States
15:00
to
16:30
Networking zone 4 (N4)
Mance Buttram
Short communication
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland
15:00
to
16:30
Networking zone 4 (N4)
Claudia Bernardini
Short communication
Individual and structural factors associated with recent hepatitis C testing in people who inject drugs: gender-based analyses of the Cosinus Cohort
15:00
to
16:30
Networking zone 4 (N4)
Ilhame Anwar
Oral presentation
2. Where does the gambling surplus come from? Outline of a theory of asymmetric market
15:00
to
16:30
Insights zone 3 (I3)
Pekka Sulkunen
Short communication
Real-world hepatitis C treatment outcomes among people who inject drugs at the Stockholm needle exchange program, Sweden
15:00
to
16:30
Networking zone 4 (N4)
Martin Kåberg
Oral presentation
3. The framing of commercial determinants of harm: challenges for regulation in the UK
15:00
to
16:30
Insights zone 3 (I3)
Heather Wardle,
Gerda Reith
Short communication
Educations for safer injection in the Mobile Drug Consumption Room in Lisbon
15:00
to
16:30
Networking zone 4 (N4)
Ângela Leite
Oral presentation
4. Meta-analysis of self-regulation discourses
15:00
to
16:30
Insights zone 3 (I3)
Gerda Reith
Short communication
Real time surveillance on the impact of restrictions on harm reduction services to improve responsiveness and reduce harms in unprecedented times
15:00
to
16:30
Networking zone 4 (N4)
Josie Smith
Oral presentation
5. Ways gambling industry pursues influence with policymakers
15:00
to
16:30
Insights zone 3 (I3)
Peter J. Adams
Short communication
Integrating hepatitis C treatment in methadone clinic in Ukraine: perspectives of participants and providers.
15:00
to
16:30
Networking zone 4 (N4)
Tetiana Kiriazova
Oral presentation
1. State-owned gambling in global competitive environment
15:00
to
16:30
Insights zone 3 (I3)
Johanna Järvinen-Tassopoulos
Short communication
Harm reduction services in the Netherlands: recent developments and challenges.
15:00
to
16:30
Networking zone 4 (N4)
Nadine G.M. van Gelder
Oral presentation
Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.
15:00
to
16:30
Knowledge market 3 (K3)
Jan Gryczynski
Oral presentation
Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon
15:00
to
16:30
Knowledge market 3 (K3)
Filipa Barata
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Discussion
What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?
15:00
to
16:30
Knowledge market 1 (K1)
Anne Whittaker
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset
15:00
to
16:30
Central square 2 (C2)
Òscar Miró
Oral presentation
4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020
15:00
to
16:30
Central square 2 (C2)
Isabelle Giraudon
Oral presentation
Who is using take-home naloxone? An examination of super-savers
15:00
to
16:30
Central square 3 (C3)
Desiree Eide
Oral presentation
Examining health care from the drug user perspective: what works, what doesn't and what needs to change
15:00
to
16:30
Central square 3 (C3)
Mary Ellen Harrod
Oral presentation
An Evaluation of the Co-Design of an Anti-Stigma Training Programme
15:00
to
16:30
Central square 3 (C3)
Sonam Prakashini Banka
Oral presentation
Once you’ve addressed your drinking, we’ll address your mental health': A qualitative exploration of patient and providers’ experiences of services for co-occurring heavy drinking and depression in North East England
15:00
to
16:30
Central square 3 (C3)
Amy O'Donnell
Oral presentation
Police officers’ attitudes and practices toward harm reduction services in Sweden – a qualitative study
15:00
to
16:30
Central square 3 (C3)
Johan Nordgren
Oral presentation
1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network
15:00
to
16:30
Central square 2 (C2)
Benjamin Crulli
Oral presentation
2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs
15:00
to
16:30
Central square 2 (C2)
Eva-Carina Heier
Oral presentation
0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction
15:00
to
16:30
Central square 2 (C2)
Paul Dargan
16:50
Oral presentation
Adolescent substance use, self-harm and suicide: Findings from the Northern Finland Birth Cohort 1986.
16:50
to
18:20
Main stage
Solja Niemelä
Oral presentation
Restricting access to means: Public health approaches to reduce drug- and alcohol-related self-harm.
16:50
to
18:20
Main stage
Eve Griffin
Oral presentation
Suicide and self-harm during COVID-19 and beyond.
16:50
to
18:20
Main stage
Navneet Kapur
Oral presentation
3. Brain reward function in young people with a dsm-5 diagnosis of Cannabis Use Disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Valentina Lorenzetti
Oral presentation
1. Cannabis use disorder and the brain: What’s culture got to do with it?
16:50
to
18:20
Knowledge market 2 (K2)
Janna Cousijn
Oral presentation
2. Resting state functional connectivity of the dorsal attention network in cannabis use disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Lisa-Marie Greenwood
Oral presentation
4. Neural response to reward anticipation after acute exposure to cannabis with and without cannabidiol in adults and adolescents
16:50
to
18:20
Knowledge market 2 (K2)
Martine Skumlien
Oral presentation
5. Acute effects of four CBD:THC ratios on attentional bias to cannabis and food cues: a randomized, double-blind, crossover study
16:50
to
18:20
Knowledge market 2 (K2)
Dominic Oliver
18:30
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge clusterrandomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Havard Midgard
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Friday, 25 November
09:00
Keynote presentation
A social inequities viewpoint to reducing alcohol-related harm
09:00
to
10:30
Main stage
Pia Mäkelä
Keynote presentation
What did we learn about recent trends in underage drinking: Secular trends, shifts, and relations to other substance use
09:00
to
10:30
Main stage
Jasmina Burdzovic
Keynote presentation
Can brief interventions ever really take on the alcohol industry and win?
09:00
to
10:30
Main stage
Jim McCambridge
Oral presentation
An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial
09:00
to
10:30
Central square 2 (C2)
Liam Acheson
Oral presentation
Treatment Seeking Pattern of Relapse Cases of Substance Use Disorder in Bangladesh
09:00
to
10:30
Central square 2 (C2)
Iqbal Masud
Oral presentation
Recovery and substitute addictions
09:00
to
10:30
Central square 2 (C2)
Deborah Louise Sinclair
Oral presentation
Determinants of recovery capital among persons in early and stable recovery from drug addiction
09:00
to
10:30
Central square 2 (C2)
Wouter Vanderplasschen
10:50
Oral presentation
1. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences
10:50
to
12:20
Insights zone 4 (I4)
Anne Berit Bech
Oral presentation
4. Have predictors of drug addiction relapse changed during the COVID-19 pandemic? A prospective study of recovery pathways in the Netherlands, Belgium and UK
10:50
to
12:20
Insights zone 4 (I4)
Thomas Martinelli
Oral presentation
5. The impacts of COVID-19 pandemic on drug purchasing behaviours of people who use methamphetamine in Victoria, Melbourne.
10:50
to
12:20
Insights zone 4 (I4)
Kasun Rathnayake
Oral presentation
2. A rapid assessment of take-home naloxone provision during COVID-19 in Europe
10:50
to
12:20
Insights zone 4 (I4)
Rebecca Mc Donald
Oral presentation
3. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway
10:50
to
12:20
Insights zone 4 (I4)
Gabrielle K. Welle-Strand
Oral presentation
Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Sarah Larney
Oral presentation
Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.
10:50
to
12:20
Knowledge market 3 (K3)
Anna Hernández-Rubio
Oral presentation
The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Nicola Jones
Oral presentation
Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK
10:50
to
12:20
Knowledge market 3 (K3)
Andrew McAuley
e-poster
Needs, Expectations and Reinforcement Mechanisms in Online Buying-Shopping Disorder
10:50
to
12:20
Networking zone 2 (N2)
Annica Kessling
e-poster
iControl: An approach of addiction prevention and digital self-regulation strategies
10:50
to
12:20
Networking zone 2 (N2)
Eurico Martins
e-poster
Smartphone and vulnerability profiles: the role of the absent minded use of smartphone, in mediating and explain the causal relationship between mind wandering and internet addiction. An extended mind perspective.
10:50
to
12:20
Networking zone 2 (N2)
Lorenzo Nelli
e-poster
Addictive Facebook Use Psychoneurobiological effect and its relationship with social alienation among university students
10:50
to
12:20
Networking zone 2 (N2)
Youcef Kaddouri
e-poster
Gamification: Promote healthy use of technology in the psychotherapy setting´s with Missão 2050 Game
10:50
to
12:20
Networking zone 2 (N2)
Pedro Fernandes
e-poster
Profiling Instagram users: how personality traits and psychological distress affect usage motives, FoMO, and Problematic Instagram Use.
10:50
to
12:20
Networking zone 2 (N2)
Virginia Pupi
e-poster
Does the use of mobile devices by preschool children differentiate their cognitive functioning?
10:50
to
12:20
Networking zone 2 (N2)
Magdalena Rowicka
e-poster
Effectiveness of a web-based self-help tool to reduce problem gambling: A randomized controlled trial
10:50
to
12:20
Networking zone 2 (N2)
Michael Schaub
e-poster
The effects of Attachment, Temperament and Self-Esteem on Technology Addiction: a Mediation Model among Young Adults
10:50
to
12:20
Networking zone 2 (N2)
Chiara Remondi
e-poster
A cross-cultural study on the problematic use of dating apps: The influence of some psychological factors
10:50
to
12:20
Networking zone 2 (N2)
Filipa Calado
Oral presentation
Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork
10:50
to
12:20
Central square 3 (C3)
Fabrice Guilbaud
Oral presentation
New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain
10:50
to
12:20
Central square 3 (C3)
Adrià Quesada
Oral presentation
5. Drug use among non-binary persons in Europe: findings from a web survey
10:50
to
12:20
Networking zone 3 (N3)
Cristiana Vale Pires
Oral presentation
1. What is gender and why it is necessary to incorporate a gender perspective in the drug field? Evolution of key theoretical concepts in the area of gender and trends influencing the drug field
10:50
to
12:20
Networking zone 3 (N3)
Analia Torres
Oral presentation
2. Gender differences in drug use from a social perspective
10:50
to
12:20
Networking zone 3 (N3)
Nuria Romo
Oral presentation
3. Sex differences in drug use and drug addiction from a neuroscience perspective
10:50
to
12:20
Networking zone 3 (N3)
Anne Marije Kaag
Oral presentation
4. Using an intersectional risk environment approach to understand health and drug outcomes: Looking across social locations
10:50
to
12:20
Networking zone 3 (N3)
Alexandra B. Collins
Oral presentation
6. Implementing a gender dimension in drug policy and practice: findings from the Pompidou Group handbook for practitioners and decision makers
10:50
to
12:20
Networking zone 3 (N3)
Sarah Morton
Oral presentation
Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021
10:50
to
12:20
Central square 3 (C3)
Ruben Vrolijk
Oral presentation
Shifting stages of ATS use and evidence-based intervention for risk reduction
10:50
to
12:20
Central square 3 (C3)
Nienke Liebregts
Oral presentation
Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.
10:50
to
12:20
Central square 3 (C3)
Ruben Van Beek
Oral presentation
PnP/CHEMSEX a means of surviving post-migration
10:50
to
12:20
Knowledge market 4 (K4)
Alexandre Brulotte
Oral presentation
Don’t cure, but care': affirmative intervention amongst men of sexual and gender diversity in the context of chemsex
10:50
to
12:20
Knowledge market 4 (K4)
Yannick Gaudette
Oral presentation
Identity matters in understanding gay and bisexual men's injecting drug use: a grounded theory study
10:50
to
12:20
Knowledge market 4 (K4)
Sophia Elvira Schroeder
Oral presentation
Interpersonal needs of gay, bisexual, and other msm who practice sexualized substance use: a critical component in treating substance use disorders among sexual minorities
10:50
to
12:20
Knowledge market 4 (K4)
Joseph De Piano
Oral presentation
The needs of professionals working on sexualized substance use and its implications for health and social services
10:50
to
12:20
Knowledge market 4 (K4)
Jorge Flores-Aranda
Discussion
Recent developments in the gender field: the EIGE’s perspective
10:50
to
12:20
Networking zone 3 (N3)
Oral presentation
Troubling trends in global alcohol consumption and harms
10:50
to
12:20
Main stage
Jürgen Rehm
Oral presentation
2. Changing risk perception on alcohol consumption
10:50
to
12:20
Main stage
Carina Ferreira-Borges
Oral presentation
3. The Gut-Brain Axis in AUD - still valid?
10:50
to
12:20
Main stage
Philippe de Timary
Oral presentation
1. Presentation of the project "Alcohol no ordinary commodity (ANOC) vx 3"
10:50
to
12:20
Main stage
Jürgen Rehm
4. The EUFAS-EAR European Addiction Award 2022
10:50
to
12:20
Main stage
13:20
Short communication
A Literature Review, using a Systematic Approach, on Effective Interventions and Approaches in the Delivery of Integrated Alcohol Services in Community Settings
13:20
to
14:50
Networking zone 4 (N4)
Elizabeth McCarthy
Short communication
Influence of alcohol use and other addictive disorders in the costs of emergency department frequent use
13:20
to
14:50
Networking zone 4 (N4)
Clara Oliveras Salvà
Short communication
Social alcohol cue reactivity in the brain: role of craving and social processes in adolescent and adult alcohol users
13:20
to
14:50
Networking zone 4 (N4)
Lauren Kuhns
Short communication
Alcohol Poisoning Outbreak in Iranian Adult Population During the COVID-19 Pandemic: A Prospective Cross-sectional Linkage Study from 13 Toxicology Referral Centers in Iran
13:20
to
14:50
Networking zone 4 (N4)
Hossein Hassanian-Moghaddam
Short communication
Novel interventions to help citizens with hazardous substance use and prevent driving under the influence of alcohol or drugs (DUI)
13:20
to
14:50
Networking zone 4 (N4)
Kristine Rømer Thomsen
Short communication
Young, drunk, and fast: the paradoxical effects of hazardous drinking on cognitive performance in younger adults
13:20
to
14:50
Networking zone 4 (N4)
Anna Powell
Short communication
Initial efficacy of a new goal-oriented intervention for impulsive and sensation-seeking adolescents involving a digital game and MI-based interview
13:20
to
14:50
Networking zone 4 (N4)
Nuri Wieland
Oral presentation
Comparing characteristics of suicide to non-suicide drug poisoning, by sex, in Ireland.
13:20
to
14:50
Knowledge market 2 (K2)
Ena Lynn
Oral presentation
Characteristics associated with suicide among people who use drugs in Ireland 2015 to 2017: a repeated cross-sectional study
13:20
to
14:50
Knowledge market 2 (K2)
Suzi Lyons
Oral presentation
Implementation of a community-based psychiatric intervention among people who inject drugs in the City of Haiphong, Vietnam: the DRIVE-Mind project
13:20
to
14:50
Knowledge market 2 (K2)
Laurent Michel
Oral presentation
Hazardous, harmful and dependent alcohol use in Crisis Resolution Team patients: relationship with death or service recontact after a suicidal crisis.
13:20
to
14:50
Knowledge market 2 (K2)
John Robins
Oral presentation
The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa
13:20
to
14:50
Knowledge market 2 (K2)
Nirvana Morgan
Oral presentation
2. The endocannabinoid system and drug addiction: basal and stress-related endocannabinoid plasma levels in chronic cocaine users and prescription opioid users
13:20
to
14:50
Central square 4 (C4)
Sara Kroll
Oral presentation
3. The endocannabinoid system as a potential buffer against the development of a substance use disorder following childhood trauma exposure
13:20
to
14:50
Central square 4 (C4)
Leah M. Mayo
Oral presentation
4. Understanding the mechanisms that link childhood stress with risk of addiction
13:20
to
14:50
Central square 4 (C4)
Molly Carlyle
Oral presentation
5. Is opioid liking driven by relief or reward? Evidence from clinical and experimental studies of acute stress
13:20
to
14:50
Central square 4 (C4)
Isabell M. Meier
Oral presentation
TitleDeterminants of psychological distress during the COVID-19 pandemic among people who use drugs in Montreal, Canada
13:20
to
14:50
Knowledge market 2 (K2)
Iuliia Makarenko
Oral presentation
Alcohol, tobacco and cannabis use and mental health as well as other associated factors during the COVID-19 pandemic among German university students
13:20
to
14:50
Knowledge market 2 (K2)
Stefanie Helmer
Oral presentation
1. Cue-induced cocaine craving enhances psychosocial stress and vice versa in chronic cocaine users
13:20
to
14:50
Central square 4 (C4)
Boris Quednow
Oral presentation
Seven years with take-home naloxone for overdose prevention in Norway: who are the first responders and how do they perform?
13:20
to
14:50
Knowledge market 3 (K3)
Øystein Bruun Ericson
Oral presentation
Post-Overdose Outreach Programs in Massachusetts: Lessons Learned, Impact and Best Practice Guidance
13:20
to
14:50
Knowledge market 3 (K3)
Alexander Walley
Oral presentation
The impact of the WHO/UNODC S-O-S training package on opioid overdose response knowledge and attitudes
13:20
to
14:50
Knowledge market 3 (K3)
Paul Dietze
Oral presentation
Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform overdose prevention efforts
13:20
to
14:50
Knowledge market 3 (K3)
Nanor Minoyan
Oral presentation
Substance-related Consequences, Dependence and Substance Use Disorder: Promising new model taking clinical and statistical points of view into consideration
13:20
to
14:50
Central square 1 (C1)
Rosalie Genois
e-poster
Gender differences in HIV prevalence and all-cause mortality among people who inject drugs (PWID) in Estonia.
13:20
to
14:50
Networking zone 1 (N1)
Maris Salekesin
Oral presentation
Language and concepts in alcohol use disorder: how framing affects stigma and recovery
13:20
to
14:50
Central square 1 (C1)
James Morris
e-poster
Interaction between Alcohol Use Disorder, APOE4 and Cognitive Decline in patients undergoing an alcohol detoxification program
13:20
to
14:50
Networking zone 1 (N1)
Laura Orio
Oral presentation
Drinking patterns across Europe. Do beverage preferences matter?
13:20
to
14:50
Central square 1 (C1)
Janusz Sieroslawski
e-poster
Functional Connectivity in a Triple-Network Saliency Model is Associated with Real-Life Self-Control
13:20
to
14:50
Networking zone 1 (N1)
Klaus-Martin Krönke
Oral presentation
Emerging Issues in the Management of Conflict of Interest
13:20
to
14:50
Central square 1 (C1)
Matej Košir
e-poster
Lifestyle risk factors and racial and ethnic inequality in mortality: Decomposing differential exposure and vulnerability in the United States
13:20
to
14:50
Networking zone 1 (N1)
Klajdi Puka
Oral presentation
Reproducibility and translation in addiction research
13:20
to
14:50
Central square 1 (C1)
Rainer Spanagel
e-poster
Demographic and socio-structural factors associated with non-fatal overdose among patients enrolled in the OPTIMA trial
13:20
to
14:50
Networking zone 1 (N1)
Hannah Crepeault
e-poster
Acceptance-based, intersectional stigma coping intervention for people with HIV who inject drugs – an RCT in St. Petersburg, Russia
13:20
to
14:50
Networking zone 1 (N1)
Karsten Lunze
e-poster
Novel Psychoactive Substances (NPS) related health responses implemented in Europe through the lens of an intersectional risk environment approach
13:20
to
14:50
Networking zone 1 (N1)
Jessica Neicun
e-poster
Alcohol Consumption during a Pandemic Lockdown Period and Change in Alcohol Consumption Related to Worries and Pandemic Measures
13:20
to
14:50
Networking zone 1 (N1)
Silvia Eiken Alpers
15:30
Keynote presentation
Providing care in a time of war — perspectives from Ukraine
15:30
to
16:00
Main stage
Irina Pinchuk